Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
24 likes 19mo
Topic summary
Revisiting: What a well-designed human trial of a secretagogue would look like
This is a generated summary. It shows the 9 most-liked posts from a topic of 75, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
Okafor, post #3: The reason well-designed human trial keeps being re-asked is that the answer is conditional and people quote it without the condition. It is not that the answer is unknown. Go to post
Research-use-only secretagogues are not approved for human use. That statement is doing real work in this subcategory, where the published evidence base is thinner than the volume of confident discussion.
methods_draft, post #12: One caution on well-designed human trial: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is rarely stated. Go to post
That reframing is the whole thing. The facts I already had.
t.wojcik, post #10: No notes. Posting so the count is not one. Go to post
Everything in post #33 holds. The case it does not cover is the one I have.
The strongest argument against my own position on well-designed human trial, stated as well as I can state it, since nobody else has yet.
a.weiss, post #37: Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach. Go to post
Adding the measurement that post #38 says would settle it.
Well-designed human trial: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
h.ramos, post #46: Hexarelin and the earlier peptidyl secretagogues have more published human data than the newer ones and a less favourable profile, which is worth knowing before treating "newer" as "better characterised". Worth reading the earlier posts in this thread before acting on mine. Go to post
The most useful single question to ask about any compound in this family is what the published human evidence actually consists of. In several cases the honest answer is a handful of small studies.
Reframing well-designed human trial slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.
28 likes 18mo
f.demir, post #59: Tesamorelin has an approved indication in HIV-associated lipodystrophy. That is the only compound in this class with a registration-quality evidence base from a proper trial programme. Generalising from that narrow population to healthy adults is a substantial extrapolation. Go to post
Adding the measurement that post #68 says would settle it.
Hexarelin and the earlier peptidyl secretagogues have more published human data than the newer ones and a less favourable profile, which is worth knowing before treating "newer" as "better characterised".
I have left out the parts I could not verify.
Read the full topic (75 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Evidence quality in the secretagogue literature: an honest assessment
Evidence quality in the secretagogue literature: an honest assessment Writing it up because I had to work it out twice and would rather nobody else did. I have spent a fortnight trying to pin evidence quality…
|
2 | 25k | 9d | |
|
Follow-up: Evidence quality in the secretagogue literature: an honest assessment
On the subject in the title: Evidence quality in the secretagogue literature: an honest assessment Working notes rather than a conclusion. A follow-up question about Evidence quality that I did not know to…
|
+20 | 24 | 18k | 4mo |
|
Reading a rodent study on a secretagogue without over-extrapolating
Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. Reading a rodent study, and specifically the version…
|
+50 | 54 | 32k | 10mo |
|
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. Asking about GHRH analogues versus ghrelin mimetics…
|
+47 | 53 | 6.9k | 2h |
|
IGF-1 as a surrogate endpoint and its limitations
IGF-1 as a surrogate endpoint and its limitations Writing it up because I had to work it out twice and would rather nobody else did. IGF-1, and specifically the version of it that the documentation does not…
|
+5 | 9 | 35k | 4mo |
Related topics — sharing the tags CJC-1295, observational data, needs a source
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
A claim built entirely on a subgroup analysis
A claim built entirely on a subgroup analysis Writing it up because I had to work it out twice and would rather nobody else did. I would like to disagree carefully with the settled view on claim built, and I…
|
+71 | 80 | 1.1k | 14mo |
|
A preprint whose numbers changed substantially at publication — what changed since
On the subject in the title: A preprint whose numbers changed substantially at publication — what changed since Working notes rather than a conclusion. A preprint question rather than a question about the…
|
+3 | 7 | 125 | 8mo |
|
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset
On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. The question about BPC-157 that I actually want…
|
+77 | 84 | 54k | 11mo |
|
Research-use-only status: what it means legally and practically — does this still hold?
Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Asking about Research-use-only status directly, because I…
|
2 | 309 | 9mo | |
|
The "under review" status pill and when a moderator applies it — a second dataset
The "under review" status pill and when a moderator applies it — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. A question about how this site should cite…
|
+50 | 54 | 1.4k | 11mo |